Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial

Abstract

Patients with myeloid leukemia of Down syndrome (ML-DS) have favorable event-free survival (EFS), but experience significant treatment-related morbidity and mortality. ML-DS blast cells ex vivo have increased sensitivity to cytarabine (araC) and daunorubicin, suggesting that optimizing drug dosing may improve outcomes while reducing toxicity. The Children's Oncology Group (COG) AAML0431 trial consisted of 4 cycles of induction and 2 cycles of intensification therapy based on the treatment schema of the previous COG A2971 trial with several modifications. High-dose araC (HD-araC) was used in the second induction cycle instead of the intensification cycle, and 1 of 4 daunorubicin-containing induction cycles was eliminated. For 204 eligible patients, 5-year EFS was 89.9% and overall survival (OS) was 93.0%. The 5-year OS for 17 patients with refractory/relapsed leukemia was 34.3%. We determined the clinical significance of minimal residual disease (MRD) levels as measured by flow cytometry on day 28 of induction I. MRD measurements, available for 146 of the 204 patients, were highly predictive of treatment outcome; 5-year disease-free survival for MRD-negative patients (n = 125) was 92.7% vs 76.2% for MRD-positive patients (n = 21) (log-rank P = .011). Our results indicated that earlier use of HD-araC led to better EFS and OS in AAML0431 than in past COG studies. A 25% reduction in the cumulative daunorubicin dose did not impact outcome. MRD, identified as a new prognostic factor for ML-DS patients, can be used for risk stratification in future clinical trials. This trial was registered at www.clinicaltrials.gov as #NCT00369317.

© 2017 by The American Society of Hematology.

Figures

Figure 1.

Event-free survival, overall survival, and cumulative incidence to relapse of patients treated on AAML0431 and A2971 ARM B. (A) EFS for n = 204 eligible patients on AAML0431 and n = 126 eligible patients 0 to 4 year olds with AML/MDS on A2971. (B) OS for n = 204 eligible patients on AAML0431 and n = 126 eligible patients 0 to 4 year olds on A2971, arm B. (C) Cumulative incidence of relapse for patients classified with AML (n = 144) and MDS (n = 60).

Figure 2.

Consolidated Standards for Reporting of Trials (CONSORT) diagram. *One patient had a nonrelapse death occurring 2 months postwithdrawal.

Figure 3.

OS for patients with refractory/relapsed leukemia or SMN.

Figure 4.

Patient outcome in relation to MRD status at day 28 of Induction I. (A) DFS comparing patients with MRD vs without MRD at day 28 collection. (B) OS comparing patients with MRD vs without MRD at day 28 collection.